Logo image of AGEN

AGENUS INC (AGEN) Stock Price, Quote, News and Overview

NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD

3.32  -0.13 (-3.77%)

After market: 3.36 +0.04 (+1.2%)

AGEN Quote, Performance and Key Statistics

AGENUS INC

NASDAQ:AGEN (2/21/2025, 8:00:20 PM)

After market: 3.36 +0.04 (+1.2%)

3.32

-0.13 (-3.77%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High19.69
52 Week Low2.5
Market Cap77.89M
Shares23.46M
Float23.13M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-12 2025-03-12/amc
IPO02-04 2000-02-04


AGEN short term performance overview.The bars show the price performance of AGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

AGEN long term performance overview.The bars show the price performance of AGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AGEN is 3.32 USD. In the past month the price decreased by -11.7%. In the past year, price decreased by -75.66%.

AGENUS INC / AGEN Daily stock chart

AGEN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About AGEN

Company Profile

AGEN logo image Agenus Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Lexington, Massachusetts and currently employs 389 full-time employees. The company went IPO on 2000-02-04. Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. The company is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Company Info

AGENUS INC

3 Forbes Rd

Lexington MASSACHUSETTS 02421 US

CEO: Garo H. Armen

Employees: 389

Company Website: https://agenusbio.com/

Investor Relations: https://investor.agenusbio.com/

Phone: 17816744400

AGENUS INC / AGEN FAQ

What is the stock price of AGENUS INC today?

The current stock price of AGEN is 3.32 USD. The price decreased by -3.77% in the last trading session.


What is the ticker symbol for AGENUS INC stock?

The exchange symbol of AGENUS INC is AGEN and it is listed on the Nasdaq exchange.


On which exchange is AGEN stock listed?

AGEN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AGENUS INC stock?

11 analysts have analysed AGEN and the average price target is 8.16 USD. This implies a price increase of 145.78% is expected in the next year compared to the current price of 3.32. Check the AGENUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AGENUS INC worth?

AGENUS INC (AGEN) has a market capitalization of 77.89M USD. This makes AGEN a Micro Cap stock.


How many employees does AGENUS INC have?

AGENUS INC (AGEN) currently has 389 employees.


What are the support and resistance levels for AGENUS INC (AGEN) stock?

AGENUS INC (AGEN) has a support level at 3.2 and a resistance level at 3.34. Check the full technical report for a detailed analysis of AGEN support and resistance levels.


Is AGENUS INC (AGEN) expected to grow?

The Revenue of AGENUS INC (AGEN) is expected to decline by -10.52% in the next year. Check the estimates tab for more information on the AGEN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AGENUS INC (AGEN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AGENUS INC (AGEN) stock pay dividends?

AGEN does not pay a dividend.


When does AGENUS INC (AGEN) report earnings?

AGENUS INC (AGEN) will report earnings on 2025-03-12, after the market close.


What is the Price/Earnings (PE) ratio of AGENUS INC (AGEN)?

AGENUS INC (AGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.24).


What is the Short Interest ratio of AGENUS INC (AGEN) stock?

The outstanding short interest for AGENUS INC (AGEN) is 12.65% of its float. Check the ownership tab for more information on the AGEN short interest.


AGEN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AGEN. When comparing the yearly performance of all stocks, AGEN is a bad performer in the overall market: 93.17% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AGEN. AGEN may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AGEN Financial Highlights

Over the last trailing twelve months AGEN reported a non-GAAP Earnings per Share(EPS) of -11.24. The EPS increased by 31.46% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -95.55%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%3.75%
Sales Q2Q%3.28%
EPS 1Y (TTM)31.46%
Revenue 1Y (TTM)59%

AGEN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to AGEN. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 12.65% and a revenue growth -10.52% for AGEN


Ownership
Inst Owners41.6%
Ins Owners1.29%
Short Float %12.65%
Short Ratio6.65
Analysts
Analysts74.55
Price Target8.16 (145.78%)
EPS Next Y12.65%
Revenue Next Year-10.52%